Multiple Myeloma

Expert faculty review and share their insights and perspectives on key findings in multiple myeloma presented at the 2020 ASH Annual Meeting.

Share

Program Content

Activities

  • ClinicalThought
    Expert Selections From ASH 2020: Multiple Myeloma
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 08, 2021

    Expires: March 07, 2022

  • Podcast
    Expert Insights on Highlights From ASH 2020 on Multiple Myeloma
    Conference Coverage
    Podcast Episodes
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 12, 2021

    Expires: March 11, 2022

  • Expert Analysis
    Key Studies in Myeloma: CCO Independent Conference Highlights of the 2020 Virtual ASH Annual Meeting
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 22, 2021

    Expires: March 21, 2022

Activities

Phase I AMG 701
First-in-Human Phase I Study of AMG 701: Anti-BCMA Bispecific Antibody in Patients With R/R MM
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2020

PRIME: P-BCMA-101 in R/R MM
PRIME Phase I/II Trial of P-BCMA-101: Novel CAR T-Cell Therapy in R/R Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2020

Expires: December 06, 2021

Teclistamab in R/R MM
Phase I Trial: Updated Analysis of BCMA x CD3 Bispecific Antibody Teclistamab (JNJ-64007957) in Patients With R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2020

ALGONQUIN Part 1
ALGONQUIN Part 1: Phase I Trial of Belantamab Mafodotin With Pomalidomide/Dexamethasone in Patients With R/R Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2020

Expires: December 07, 2021

Cevostamab in R/R MM
Cevostamab: Novel FcRH5 x CD3 Bispecific Antibody in Patients With R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

GRIFFIN: DVRd vs VRd Maintenance Phase Update
GRIFFIN Maintenance Phase Update: Daratumumab + VRd → Dara-R vs VRd → R Alone for ASCT-Eligible Patients With Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

Expires: December 08, 2021

DREAMM-2: Outcomes by Prior Tx
Phase II DREAMM-2 Study of Belantamab Mafodotin in R/R MM: Outcomes by Number of Prior Therapies
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

Expires: December 08, 2021

TOURMALINE-MM2: IRd in ND MM
TOURMALINE-MM2: Oral Ixazomib-Rd vs Placebo-Rd for ASCT-Ineligible Patients With Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

Expires: December 08, 2021

STOMP: Selinexor + Pom/Dex
STOMP Phase I/II Trial: Selinexor/Pomalidomide/Dexamethasone in R/R MM After ≥ 2 Previous Therapies
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2020

Expires: December 09, 2021

APOLLO: SC Dara + Pd vs Pd
Phase III APOLLO: Daratumumab SC + Pom/Dex vs Pom/Dex Alone in Patients With R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2020

Expires: December 09, 2021

Talquetamab in R/R MM
First-in-Human Phase I Trial of GPCR5D x CD3 Bispecific Antibody Talquetamab in Patients With R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2020

Expires: December 10, 2021

CRB-402: bb21217 in R/R MM
Updated Analysis of Phase I CRB-402: bb21217 Anti-BCMA CAR T-Cell Therapy in Patients With R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2020

Expires: December 10, 2021

DREAMM-6: Belamaf + Vd in R/R MM
Phase II DREAMM-6 Arm B: Preliminary Analysis of Belantamab Mafodotin + Bortezomib/Dexamethasone in R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2020

Expires: December 10, 2021

Allogenic Anti-BCMA CAR T-Cell in R/R MM
First-in-Human Phase I UNIVERSAL Trial of Allogeneic CAR T-Cell Therapy With ALLO-715 (Anti-BCMA) and ALLO-647 (Anti-CD52) in Patients With R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2020

CARTITUDE-1: Cilta-Cel in R/R MM
CARTITUDE-1 Phase Ib/II Study of Ciltacabtagene Autoleucel: BCMA-Directed CAR T-Cell Therapy in Patients With R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

DREAMM-2: Ocular Safety
DREAMM-2: Ocular Safety During Phase II Study of Belantamab Mafodotin in R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

MEDI2228: R/R MM
BCMA-Targeted ADC MEDI2228: First-in-Human Phase I Study in Patients With R/R Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

Iberdomide + Dd or Vd in R/R MM
Phase I/II Trial of Iberdomide Plus Daratumumab/Dex or Bortezomib/Dex in R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2020

REGN5458 in R/R MM
First-in-Human Phase I Study of BCMA x CD3 Bispecific Antibody REGN5458 in Patients With R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2020

Expires: December 14, 2021

MAIA Update: D-Rd vs Rd
MAIA Updated Analysis: Phase III Study of D-Rd vs Rd for ASCT-Ineligible Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2020

Expires: December 16, 2021

Faculty

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

cover img faculity

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Provided by

ProCE Banner

Supporters

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology